Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Histone demethylase that specifically demethylates 'Lys- 27' of histone H3, thereby playing a central role in histone code. Additionally we are shipping Kdm6b Kits (2) and and many more products for this protein.
Showing 10 out of 95 products:
Human Polyclonal Kdm6b Primary Antibody for IF, IHC (p) - ABIN387862
Lu, Lu, Liao, Yu, Chung, Kao, Wu: Epithelial cell adhesion molecule regulation is associated with the maintenance of the undifferentiated phenotype of human embryonic stem cells. in The Journal of biological chemistry 2010
Show all 15 Pubmed References
Human Polyclonal Kdm6b Primary Antibody for FACS, ICC - ABIN438547
Pham, Yu, Walline, Muthukrishnan, Blum, Kaplan: Opposing roles of STAT4 and Dnmt3a in Th1 gene regulation. in Journal of immunology (Baltimore, Md. : 1950) 2013
Show all 3 Pubmed References
Human Polyclonal Kdm6b Primary Antibody for WB - ABIN387864
Shaw, Martin: Epigenetic reprogramming during wound healing: loss of polycomb-mediated silencing may enable upregulation of repair genes. in EMBO reports 2009
Data show that Spi1 (show SPI1 Antibodies) is a downstream target of histone demethylase (show MBD2 Antibodies) Jmjd3 (Jmjd3) during myelopoiesis.
loss of both kdm6ba and kdm6bb shows Kdm6b proteins share redundant and pleiotropic roles in organogenesis without impacting initial cell fate specification.
Data demonstrate that histone modifications silence promoters of numerous genes involved in zebrafish caudal (show CAD Antibodies) fin regeneration, and that Kdm6b.1 may be the histone demethylase (show MBD2 Antibodies) required during regeneration.
Our data show that chemical inhibition of the H3K27me3 demethylases Jmjd3/Utx (show KDM6A Antibodies) blunts Neurogenin3 (show NEUROG3 Antibodies)-dependent gene activation in vitro. Conversely, inhibition of the H3K27me3 methyltransferase Ezh2 (show EZH2 Antibodies) enhances both the transactivation ability of Neurogenin3 (show NEUROG3 Antibodies) in cultured cells and the formation of insulin (show INS Antibodies)-producing cells during directed differentiation from pluripotent cells
Study indicates sequential chromatin events and identifies a crucial role for Jmjd3 in regulating the efficiency of the transition from Ngn3 (show NEUROG3 Antibodies)-low to Ngn3 (show NEUROG3 Antibodies)-high cells.
When JMJD3 levels were decreased by RNA interference, the embryo development rate and quality were improved, but the knockdown of UTX (show KDM6A Antibodies) produced the opposite results.
binding of SMAD2 (show SMAD2 Antibodies)/3, the intracellular effectors of activin (show Actbeta Antibodies) signaling, was significantly enriched at the Pmepa1 (show PMEPA1 Antibodies) gene, which encodes a negative feedback regulator of TGF-beta (show TGFB1 Antibodies) signaling in cancer cells, and at the Kdm6b gene, which encodes an epigenetic regulator promoting transcriptional plasticity.
Results identified Kdm6b as a novel regulator of the pro-fibrotic signature of peritoneal foam cells.
These results suggest that the demethylase (show MBD2 Antibodies) activity of Jmjd3, but not that of Utx (show KDM6A Antibodies), affects mouse axial patterning in concert with alterations in Hox (show MSH2 Antibodies) gene expression.
Direct genetic and molecular evidence that JMJD3 is a key mediator for the kisspeptin-estrogen feedback loop.
Knockdown of Kdm6b in chondrocytes leads to abnormal cartilage development and accelerated osteoarthritis progression via inhibition of the anabolic metabolism of chondrocytes. The number of Kdm6b-positive chondrocytes was lower in osteoarthritis cartilage samples.
Preliminary evidence suggests a role of JMJD3 in removal of H3K27me3 mark from promoters of hepatic transcription factors, thus activating epigenetically poised hepatic genes in bone marrow progenitor cells prior to partial nuclear reprogramming.
Study provides evidence that miR (show MLXIP Antibodies)-148a-3p reciprocally regulates adipocyte and osteoblast differentiation through directly targeting Kdm6b.
We demonstrate that extraskeletal osteosarcoma (ESOS) may include at least two small subsets: an MDM2 (show MDM2 Antibodies)-amplified deep soft-tissue ESOS and an H3K27me3-deficient organ-based ESOS
Our results demonstrate that in the early stage of sepsis, JMJD3 contributes to high levels of neutrophil mPR3 (show PRTN3 Antibodies) expression and thereby to the production of the inflammatory cytokine IL-1beta (show IL1B Antibodies)
Computational methods identifyied H3(17-33)-derived peptides with improved binding affinity that would allow co-crystallization with the KDM6B catalytic core. A co-crystallized H3(17-33)A21M peptide had interactions between the KDM6B zinc binding domain and the H3(17-23) region. KDM6B uses the zinc binding domain to achieve H3K27me3/me2 (show CELSR1 Antibodies) specificity. A 1564 His-to-Gln substitution explains its higher affinity than KDM6A (show KDM6A Antibodies).
Taken together, the authors propose that the miR (show MLXIP Antibodies)-939-Jmjd3 axis perturbs the accessibility of hepatitis B virus enhancer II/core promoter (En II) promoter to essential nuclear factors (C/EBPalpha (show CEBPA Antibodies) and SWI (show SMARCA1 Antibodies)/SNF (show SNRPA Antibodies) complex) therefore leading to compromised viral RNA synthesis and hence restricted viral multiplication.
These results demonstrated that histone demethylase (show MBD2 Antibodies) JMJD3 regulates CD11a (show ITGAL Antibodies) expression in lupus T cells by affecting the H3K27me3 levels in the ITGAL (CD11a (show ITGAL Antibodies)) promoter region, and JMJD3 might thereby serve as a potential therapeutic target for SLE.
In this study, we showed that aberrantly upregulated JMJD3 exerts an anti-apoptotic effect in diffuse large B-cell lymphoma
Our study therefore delineates KDM6B function that links NF-kappaB (show NFKB1 Antibodies) and MAPK (show MAPK1 Antibodies) signaling pathway mediating MM cell growth and survival, and validates KDM6B as a novel therapeutic target in MM.
Our data indicate that hypoxic inhibition of JMJD3 activity reduces demethylation of H3K27me3, nucleosome removal, and hence induction of the STAT6 (show STAT6 Antibodies) target gene CCL18 (show CCL18 Antibodies), while induction of other STAT6 (show STAT6 Antibodies)-inducible genes such as SPINT2 (show SPINT2 Antibodies) remained unaffected by JMJD3.
Here, we discuss the roles of lysine 27 demethylases, JMJD3 and UTX (show KDM6A Antibodies), in cancer and potential therapeutic avenues targeting these enzymes. Despite a high degree of sequence similarity in the catalytic domain between JMJD3 and UTX (show KDM6A Antibodies), numerous studies revealed surprisingly contrasting roles in cellular reprogramming and cancer, particularly leukemia
Histone demethylase that specifically demethylates 'Lys- 27' of histone H3, thereby playing a central role in histone code. Demethylates trimethylated and dimethylated H3 'Lys-27'. Plays a central role in regulation of posterior development, by regulating HOX gene expression. Involved in inflammatory response by participating in macrophage differentiation in case of inflammation by regulating gene expression and macrophage differentiation.
jumonji domain containing 3
, lysine (K)-specific demethylase 6B
, jumonji domain containing 3, histone lysine demethylase
, lysine-specific demethylase 6B-like
, jmjC domain-containing protein 3
, jumonji domain-containing protein 3
, lysine-specific demethylase 6B
, lysine demethylase 6B
, jumonji domain-containing 3